MDMA‐assisted therapy for PTSD reduced symptoms in Phase 3 trial
The Brown University Psychopharmacology Update January 1, 2024 DOI: 10.1002/pu.31105 (opens in new tab)
Summary
AI-generated from the abstractThree sessions of MDMA-assisted therapy over three months led to significantly greater reductions in PTSD symptoms than placebo plus therapy in a Phase 3 trial. The treatment also improved functional impairment. Results were published in Nature Medicine in September 2023.
Study at a glance
| Characteristics | Randomized controlled trial Peer reviewed |
|---|---|
| Population | People with post-traumatic stress disorder |
| Duration | 3 months |
| Key finding | MDMA-assisted therapy significantly improved PTSD symptoms and functional impairment compared with placebo plus therapy. |
Abstract
Three sessions of 3,4‐methylenedioxymethamphetamine (MDMA)‐assisted therapy over 3 months significantly improved symptoms of post‐traumatic stress disorder (PTSD) compared with placebo plus therapy in a Phase 3 trial. MDMA‐assisted therapy also resulted in improvement in a measure of functional impairment. Study results were published online Sept. 14, 2023, in Nature Medicine.